Welcome to “Fly Insider,” The Fly’s weekly recap of notable insider stock transactions.
NOTABLE INSIDER PURCHASES: Significant insider purchases reported in the prior week from June 12 through June 16 include:
- Beneficial owner of Nuvectis Pharma (NVCT) Charles Mosseri Marlio purchased 32,124 shares of company stock at $17.71 per share for a total transaction amount of $568,849
- Director of Coherent (COHR) David Motley purchased 6,041 shares of company stock at $49.62 per share for a total transaction amount of $299,741
- Chairman of GameStop (GME) Ryan Cohen purchased 443,842 shares of company stock at $22.53 per share for a total transaction amount of $10,000,382
- Director of Bioventus (BVS) John Bartholdson purchased 292,126 shares of company stock at $3.38 per share for a total transaction amount of $987,181
NOTABLE INSIDER SALES: Significant insider sales in the prior week from June 12 through June 16 include:
- VP of Arteris (AIP) Paul Alpern sold 42,051 shares of company stock at $7.33 per share for a total transaction amount of $308,419
- Beneficial owner of AmerisourceBergen (ABC) Walgreens Boots Alliance sold 275,984 shares of company stock at $181.17 per share for a total transaction amount of $50,000,021
- VP of Autodesk (ADSK) Rebecca Pearce sold 1,252 shares of company stock at $220 per share for a total transaction amount of $275,440
- VP of Agilysys (AGYS) Kyle Badger sold 10,000 shares of company stock at $73.49 per share for a total transaction amount of $734,850
NOTABLE PRICE MOVEMENT AFTER INSIDER TRANSACTION: Shares of GameStop rose 23% after chairman Ryan Cohen disclosed that he had purchased 443,842 shares of company stock at $22.53 per share, while shares of Arteris fell 12% after VP Paul Alpern sold 42,051 shares of company stock at $7.33 per share.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVCT:
- Nuvectis Pharma set to join Russell 2000, Russell 3000 indexes
- Nuvectis Pharma Announces FDA Clearance of NXP900 IND
- Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights
- Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference